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Background: Temperature management is a recommended part of post-resuscitation care of comatose survivors
of cardiac arrest. A number of methods exist for temperature management, all of which have limitations. We
aimed to evaluate the performance and ease of use of a new esophageal heat transfer device (EHTD; Advanced
Cooling Therapy, Chicago, IL, USA) for temperature management of adult survivors of cardiac arrest.
Methods: We performed a prospective study from March to June 2015. Our standard protocol uses servo-
controlled water blankets supplemented with ice-cold saline in order to attain goal temperature (32°C-34°C)
within 1 hour. We substituted the EHTD for our usual water blankets, then recorded temperature over time
and adverse effects.
Main ﬁndings: A total of 14 patients were treated, withmean age 65.1± 13.7 years, andmedian weight 75.5 (70;
83) kg. Initial temperaturewas 35.3± 1.2°C.Mean cooling rate during the induction phasewas 1.12± 0.62°C/h,
time to target temperature was 60 (41; 195) min and the volume of iced ﬂuids infused was 1607 ± 858 ml (as
compared with 2–2.5 L historically). The percentage of time outside target temperature range during the
maintenance phase was 6.5% (0.0; 29.0). Rewarming rate was 0.22 (0.18; 0.31)°C/h. No major adverse effects
were observed.
Conclusion: Using the EHTD, our patient population attained goal temperatures in one hour, the volume of ice-
cold saline required to attain this cooling rate was decreased by one-third, and experienced a low percentage
of time outside target temperature range and no major adverse effects.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Temperaturemanagement is an important part of post-resuscitation
care of comatose survivors of cardiac arrest. Therapeutic hypothermia
(TH) has been a part of guidelines since 2005 [1,2], although controlled
normothermia was as successful as TH in a large, prospective, random-
ized study [3]. Both approaches to temperature management require
the capability to control and, if necessary, induce changes to body tem-
perature [2–4]. A number of methods exist for temperaturemanagementsophageal heat transfer device;
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. This is an open access article underafter cardiac arrest, all of which have limitations [5,6]. External, non-
invasive temperature management methods require direct contact with
40–90% of patients' skin, obstruct access to patient and are less efﬁcient
[4]. Intravascular methods are invasive in nature and expensive [5,7,8].
TH can be successfully induced via infusion of cold ﬂuid, however, ﬂuid
loading required to induce TH with this technique has been associated
with negative effects on ventilation parameters and greater use of di-
uretics [4,9].
The esophageal heat transfer device (EHTD; Advanced Cooling Ther-
apy, Chicago, Illinois) is a novel device designed as a silicone orogastric
tube with 3 lumens: inﬂow and outﬂow lumens for circulating water
and an orogastric suction lumen [10]. It is connected to a generic exter-
nal unit where water is cooled or heated according to differences be-
tween a patient's actual and desired temperature. It offers several
potential advantages over external methods (greater heat conducting
capability because of its proximity to the heart and great vessels, with
less obstruction of access to the patient) and is minimally invasive
when compared to intravascular methods [10–12].
We aimed to evaluate the performance and ease of use of the EHTD
for temperature management of adult survivors of cardiac arrest after
the introduction of the EHTD in our hospital.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Study design and setting
We performed a prospective data collection in a tertiary medical in-
tensive care unit (ICU) after the introduction of the EHTD in our hospi-
tal, from March to June 2015. Institutional ethics committee approval
(No 8–1/15) and patient/surrogate consent was obtained.2.2. Study population
We included all comatose adult survivors of cardiac arrest, irre-
spective of the initial recorded rhythm or location of arrest, treated
with targeted temperature management. We excluded patients
with known or suspected esophageal deformity or evidence of
esophageal trauma (eg, esophageal varices, history of esophagecto-
my, previous swallowing disorders, achalasia, etc), known ingestion
of acidic or caustic poisons within the prior 24 h, less than 40 kg of
body mass, pregnancy, terminal disease and death likely b24 h
after admission.Table 1
Patient characteristics
Patient characteristics Result
Age, mean (years ± SD) 65.1 ± 13.7
Male sex, n (%) 12 (86)
Weight, median (kg, IQR) 75.5 (70; 83)
Height, mean (cm ± SD) 174.1 ± 9.9
Initial temperature, mean (°C ± SD) 35.3 ± 1.2
Body surface area, median (m2, IQR) 1.93 (1.83; 1.98)
Out-of-hospital cardiac arrest, n (%) 11 (78)
Initial rhythm VF/pVT, n (%) 9 (64)
Initial rhythm PEA/asystole, n (%) 5 (36)
Required noradrenaline, n (%) 13 (93)
Required neromuscular blocking agents, n (%) 13 (93)
Survival to hospital discharge, n (%) 7 (50)
Good neurological outcome, n (%) 6 (43)
VF = ventricular ﬁbrillation, pVT = pulseless ventricular tachycardia, PEA = pulseless
electrical activity, ICU = intensive care unit.2.3. Study intervention
Our standard protocol for targeted temperature management in co-
matose survivors of cardiac arrest uses servo-controlled water blankets
supplemented with ice-cold saline infusion in order to attain target
temperature (32–34°C) within one hour [2,9]. In this study, we
substituted the EHTD for our usual water blankets, then recorded tem-
perature over time, and observed for any adverse effects. The EHTD is
a silicone orogastric tube designed to enable transfer of heat to and
from the patient through the esophagus via temperature-controlled
water with an additional orogastric lumen [10]. The water circulates
in a closed circuit via the inﬂow and the outﬂow lumens of the EHTD,
with water temperature regulated by an external heat exchanger. We
used an external unit with the lowest circulating water temperature of
13°C, rate of circulation 1.2 l/min and automated regulation of circulat-
ingwater temperature (CritiCool,MTRE, Rehovot, Israel) [13]. The EHTD
was inserted using a laryngoscope by orogastric intubation to a depth of
approximately 35 cm, after ﬁrst connecting the EHTD to the external
unit and turning on the water circulation to increase the rigidity of the
device. Adequate placement was conﬁrmed with auscultation above
the stomach during insuﬂation of approximately 50 ml of air. Due to
time constraint, locating the radioopaque tip of the device in stomach
on chest radiograph was performed later, after the cooling had already
started. Urinary bladder (Foley) or rectal temperature probes were
placed for temperature measurement and feedback to the external
heat exchange unit. Once inserted, the external unit was set to cooling
mode. Intravenous infusion of iced ﬂuids (normal saline or Ringer's so-
lution at 0°C-4°C) was started simultaneously at a predetermined vol-
ume of 1000 ml if initial temperature was 34.1°C to 35°C, and 20 ml/
kg body weight (rounded to 500 ml) if N35°C. Additional iced ﬂuid
was allowed if a goal temperature of 34°C or less was not achieved in
60 min after admission. During the maintenance phase, minor temper-
ature ﬂuctuations were deﬁned as ≤0.5°C above or below target tem-
perature range. No additional interventions were performed for minor
temperature ﬂuctuations. If temperature ﬂuctuations were N0.5°C,
then additional external cooling/rewarmingwas allowed if temperature
was above/below temperature range 32-34°C ± 0.5°C for more than 2
consecutive hours. Similarly, additional external cooling/rewarming
was allowed if the rate of rewarming was above/below target rate
(0.25°C-0.5°C/h) for more than 2 consecutive hours. Unwanted
rewarming during the rewarming phase was deﬁned as an increase of
body temperature N36.5°C at any point in time between 24 and 36 h
after admission.2.4. Measurements
We aimed to determine the cooling rate during the induction phase,
to evaluate the feasibility of reaching a goal temperature of ≤34.0°C
within 1 h, to measure the amount of intravenous iced ﬂuids adminis-
tered, to determine the time that patient temperature was out of the
target temperature range (32°C-34°C) during the maintenance phase,
and to evaluate the feasibility of rewarming patients at a rate of
0.25°C-0.5°C/h.We also recorded any adverse effects, estimated the suc-
cess rate of EHTD insertion, and recorded ICU survival, survival to hospi-
tal discharge and neurological outcome of patients expressed in the
Cerebral Performance Category (CPC) scale [14].
Adverse effects were deﬁned as: oral cavity, pharyngeal, esophageal
or gastric injury or bleeding, dys- or odynophagia reported by patients,
bradycardia b30/min, the need for temporary transcutaneous or
transvenous cardiac pacing, aspiration pneumonia b24 h after admis-
sion, or any other adverse effect thought to be related to the use of
EHTD. Patient temperature recording began with EHTD insertion and
was recorded in 15 min intervals for the ﬁrst hour and in hourly inter-
vals until 36 h after admission. Unstructured interviews were per-
formed with all nursing teams regarding workload associated with the
device and any issues regarding the use of the EHTD in our clinical
environment.
2.5. Data analysis
Descriptive statistics were performed. Cooling rate was derived by
dividing the difference between each patients' initial temperature and
target temperature (34.0°C) with the time that was required to reach
target temperature. The time that the temperature was out of the de-
sired range was calculated from each patient's data. Rewarming rate
was derived by dividing the difference between each patient's temper-
ature at 24 h after admission andpoint in timewhennormothermiawas
achieved with the time that was required to reach normothermia. Sta-
tistical analysis and presentation of results were performed using
Microsoft Excel 2013 (Microsoft, USA) and SigmaPlot 11.0 (Systat Soft-
ware Inc., USA).
3. Results
3.1. Baseline characteristics
A total of 14 patients were included from March to June 2015. Pa-
tient characteristics are presented in Table 1. During this study period,
12 additional patients were admitted after successful cardiopulmonary
resuscitation but were not treated with the EHTD: 4 were awake, 7
were not expected to survive 24 h, and one had suspected esophageal
pathology (all patients with return of spontaneous circulation are
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even in case comfort measures only are applied).
3.2. Main results
Details on each patient treated are shown in Table 2, and tempera-
ture changes over time are shown in Figure. A mean of 1.6 (±0.8) at-
tempts were required for successful insertion of the EHTD. In all
patients temperature was measured via the urinary bladder (Foley)
catheter. A mean cooling rate during the induction phase of TH was
1.12± 0.62°C/h. A goal temperature of ≤34.0°Cwas achieved in amedi-
an time of 60 (41.2; 195) minutes (Figure). The mean amount of intra-
venous icedﬂuids infusedwas 1607±858ml (20.9±9ml/kg BW). In 6
patients target temperaturewas not achieved in 60min after admission.
The additional volume of intravenous iced saline was 500 ml for pa-
tients no. 5, 8, 9, and 12, and 1000 ml for patients no. 2 and 14, and tar-
get temperature was eventually achieved in all patients.
During the maintenance phase, the median percentage of time out-
side the target range was 6.5% (0.0; 29.0). Overshoot cooling during the
maintenance phase occurred in 2 patients with the lowest temperature
being 31.2°C. In both cases, temperature returned to target range with-
out additional interventions. Unwanted rewarming during the mainte-
nance phase that required additional external cooling occurred in 4
patients. The duration of time that temperature was above target
range was 9 h (patient No 1), 7 h (patient No 6), 5 h (patient No 8),
and 8 h (patientNo 9), andmaximum temperatures during the episodes
of unwanted rewarmingwere 35.1°C (patient No 1), 36.1°C (patient No
6), 34.6°C (patient No 8) and 35.2°C (patient No 9). Minor temperature
ﬂuctuations of b0.5°C above target range occurred in additional 5 pa-
tients. In these patients the temperature was controlled using the
EHTD alone.
The median rate of rewarming was 0.22 (0.18; 0.31)°C/h (Figure).
Additional external rewarming was required in one patient, who died
after 4 days from cardiogenic shock and multiorgan failure.
One patient was found to have a superﬁcial pharyngeal laceration
one day after the removal of the EHTD. A local hemostatic agent was
used and no additional procedures were necessary. One patient devel-
oped radiographic signs of right lobe pneumonia within 24 h after ad-
mission. One patient required temporary transvenous pacemaker
insertion in the peri-arrest period before the insertion of EHTD orTable 2
Main results
Patient Initial bladder
temperature
(°C)
Weight
(kg)
Time to target
temperature
(min)
Cooling rate during the
induction phase (°C/h)
Vo
du
(m
1 35.2 56 45 1.6 15
2 36.0 126 240 0.5 35
3 34.4 69 15 1.6 10
4 36.3 87 60 2.4 15
5 35.1 80 180 0.4 20
6 32.6 73 0 * 0
7 35.2 75 60 1.5 15
8 36.0 91 300 0.4 25
9 35.6 83 120 0.8 20
10 34.8 76 30 1.6 10
11 34.4 82 15 1.6 10
12 36.6 59 180 0.9 15
13 34.5 75 45 0.7 10
14 37.8 70 360 0.6 25
Medians
(IQR)
or
Means
(±SD)
35.2 (34.5; 36.0) 75.5
(70;
83)
60 (41.2; 195) 1.12 ± 0.62 16
IQR = interquartile range, SD = standard deviation, * = no cooling rate was calculated beca
when rewarming was initiated, ‡ = the patient never achieved normothermia during study pinitiation of cooling. Temporary pacemaker support was successfully
discontinued after 2 h during ongoing cooling via EHTD. During treat-
ment with the EHTD a total of 5 patients experienced episodes of atrial
ﬁbrillation, 5 patients suffered nonsustained ventricular tachycardia
and one patient multiple episodes of ventricular tachycardia.
Esophagogastroduodenoscopy was performed in 1 patient for indica-
tions unrelated to the use of EHTD (preexistent microcytic anemia).
Esophagogastroduodenoscopy was performed one day after removal
of EHTD (the device was in situ for 3 days) and no changes were ob-
served that could be attributed to EHTD (chronic hiatal hernia and
chronic gastritis were present).
Patients who survived with good neurological outcome were
interviewed for symptoms of dys- and odynophagia after discharge
from the ICU and none were reported.
Seven patients (50%) survived to hospital discharge, 6 (43%) with
good neurologic outcome (CPC of 1–2) at discharge. Of 7 patients that
did not survive, 5 died in the ICU setting. In 2 patients neurologic assess-
mentwas not possible due to early death in ICU. The EHTDwas removed
after 36 h in 5 patients. In 9 patients the devicewas left in situ after com-
pletion of 36 h (mean duration 3.3 ± 1.0 days, with the longest being
5 days). The deviceswere inspected after removal and nomajor damage
to the device, such as bulging, creases, surface degradation, etc., were
visible.
Untill the removal of the EHTD it was the only orogastric or nasogas-
tric tube used, and orogastric lumen of the device was used for applica-
tion of therapy (eg. dual antiplatelet therapy in patients with acute
coronary syndrome) and for enteral feeding. Nine patients were
transported from the ICU with the device in-situ (e.g. for emergency
coronary angiography, to radiology department), and no problems
were encountered.
Unstructured interviews with nursing teams that worked with the
device revealed that the device enabled good access to the patients (in-
cluding oral hygiene), and the workload regarding temperature man-
agement was felt to be decreased.
4. Discussion
We report here our initial experience with a novel temperature
management device in a clinical setting where temperature manage-
ment is important [15,16]. Initial case series have suggested favorablelume of ﬂuids received
ring the induction phase
l)
Time out of target range during the
maintenance phase (%)
Rate of
rewarming
(°C/h)
Altogether Minor ﬂuctuations
(b0,5°C outside target
range)
00 48 18 0.11
00 0 0 0.10
00 0 0 0.20
00 4 4 0.32
00 0 0 0.26
29 4 †
00 13 13 0.30
00 31 26 0.21
00 36 9 0.25
00 0 0 0.26
00 4 4 0.63
00 9 9 ‡
00 17 17 0.26
00 0 0 0.20
07 ± 858 6.5 (0.0;
29.0)
4.0 (0.0; 13.0) 0.22 (0.18;
0.31)
use target temperature was present on admission, † = the patient was in normothermia
eriod.
Figure. Temperature changes over time. Temperature changes during the induction, maintenance and rewarming phases from ﬁrst measured temperature until 36 h after admission
expressed as median values. Box plots indicate respective interquartile ranges, whiskers extend from 10th until 90th percentile.
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larger data set to be prospectively acquired [12,17].
Standard practice in our ICU is to use servo-controlled water blan-
kets supplemented with ice-cold saline in order to attain goal tempera-
ture (32°C-34°C) within one hour [5,18,19]. Although recent data has
questioned the use of pre-hospital iced saline for induction of hypother-
mia [9], ﬂuid infusions are often required for early haemodynamic opti-
misation in patients with post-cardiac arrest syndrome [20–24]. Using
the EHTD, we were able to utilize a smaller volume of iced ﬂuids
(1607 ± 858 mL, or 20.9 ± 9 mL/kg BW) than we typically utilize
when using water blankets to attain goal temperature and smaller vol-
ume compared to that as proposed by the guidelines at the time the
study was performed (30 mL/kg BW) [2]. In a study performed in our
site using the combination of intravenous cooling and water blankets,
2125 ± 694 ml were used to induce hypothermia [25]. During the in-
duction of hypothermia we achieved a cooling rate of 1.12 (±0.62)°C/
h. Similar rates have been achieved using intravascular devices or infu-
sion of greater volumes of iced ﬂuids [8,24,25]. In one of the largest re-
cent studies to date, endovascular cooling devices were reported to
have an average cooling rate of 0.39°C/h, while surface cooling devices
were reported to have an average cooling rate of 0.27°C/h [16]. Temper-
ature control during the maintenance phase was comparable to intra-
vascular cooling catheters [16].
The ability to gradually rewarm patients is important because of loss
of protective effects of hypothermia electrolyte disturbances and an in-
crease in insulin sensitivity in case of overly rapid rate of rewarming
[3,4,26]. The EHTD enabled controlled rewarming with a median rate
of 0.22 (0.18; 0.31)°C/h, which is comparable to intravascular devices
[15,16]. Wewere unable to rewarm one patient despite supplementing
the EHTD with additional external rewarming; that patient died in car-
diogenic shock and multiorgan failure on day 4, suggesting that heat
production was compromised bymetabolic failure associatedwith irre-
versible shock [27].
No serious adverse effects were observed in our study. The superﬁ-
cial pharyngeal laceration appears likely to have been induced by oral
hygiene procedures or laryngoscopy, whichwas used during placement
of the EHTD to facilitate tongue displacement. Minor injuries to oral and
pharyngeal mucosa occur in about 5% of laryngoscopy attempts [28].
The right sided pneumonia that presented within 24 h after admission
was thought by the treating clinicians to be caused by aspiration prior
to intubation. Pneumonia occurs in up to 40% of patients who undergo
therapeutic hypothermia [29]. The incidence of supraventricular and
ventricular dysrhythmias was also similar to previously published data
for survivors of cardiac arrest [4,29].
Insertion of the EHTD was straightforward and was successful in all
patients. All therapeutic and diagnostic procedures (ECG, echocardiog-
raphy, coronary angiography, brain CT, oral hygiene etc.) could beperformed with the device in-situ. The device was successfully used
for application of therapy and for enteral feeding, obviating the need
for additional naso- or oro-gastric feeding tube.
4.1. Limitations
Because our protocol utilizes cold saline to enhance the speed to goal
temperature, we are unable to isolate the speciﬁc cooling rate of the
EHTD. Nevertheless, when compared to our historical use of water blan-
kets as the primary temperature control modality, we found that we
could reduce our use of cold saline by approximately one third [25]. Fu-
ture iterations of our standard temperature management protocol may
result in our abandoning the use of cold saline, enabling further charac-
terization of the speciﬁc cooling rate of the EHTD. Also, we utilized an
external heat exchange unit that attains a low temperature of circulat-
ing water of 13°C, and a rate of circulation of 1.2 l/min, as compared to
4°C and 2.6 l/min in other external units [11,13,17,30]. Higher cooling
rates and further improvements in temperature control might be ex-
pected with a higher water ﬂow rates and lower minimum tempera-
tures. We did not formally study the clinician workload associated
with the device; although informal interviews with nursing teams
were performed, a standardized questionnaire would offermore granu-
larity and validity.
To conclude, using the EHTD, our patient population attained goal
temperatures in 1 hour, using approximately two-thirds the amount
of ice-cold saline typically required to attain this cooling rate, and
experiencing a low percentage of time outside target temperature
range. The EHTD could potentially be a useful tool for targeted temper-
ature management in survivors of cardiac arrest.References
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